Trombosis venosa portal e hiperplasia nodular regenerativa hepática; posible efecto adverso asociado a bevacizumab y oxaliplatino

Nodular regenerative hyperplasia (NRH) consists in diffuse transformation of the hepatic parenchyma into small regenerative nodules without fibrosis, secondary to vascular occlusion and flow alterations. This gives a nodular appearance to theliver, as there is atrophy and compensatory hypertrophy of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fluxá C,Daniela, Salas M,Sebastián, Regonesi M,Carlos, Contreras M,Luis, Wash F,Alex, Silva P,Guillermo
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2013
Materias:	Antibodies monoclonal humanized Bevacizumab Focal nodular hyperplasia Hypertension portal Organometallic compounds Oxaliplatin
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013001000017
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872013001000017
record_format	dspace
spelling	oai:scielo:S0034-988720130010000172014-10-10Trombosis venosa portal e hiperplasia nodular regenerativa hepática; posible efecto adverso asociado a bevacizumab y oxaliplatinoFluxá C,DanielaSalas M,SebastiánRegonesi M,CarlosContreras M,LuisWash F,AlexSilva P,Guillermo Antibodies monoclonal humanized Bevacizumab Focal nodular hyperplasia Hypertension portal Organometallic compounds Oxaliplatin Nodular regenerative hyperplasia (NRH) consists in diffuse transformation of the hepatic parenchyma into small regenerative nodules without fibrosis, secondary to vascular occlusion and flow alterations. This gives a nodular appearance to theliver, as there is atrophy and compensatory hypertrophy of hepatocytes. We reporta 69-year-old male who suffered of colon cancer and was treated with Oxaliplatin (OX) and Bevacizumab (B). During treatment with B the patient presented a partial thrombosis of the portal vein, that one year later became permeable. Esophageal varices were found in an upper digestive endoscopy. Hepatic tests were normal. Aliver biopsy was performed and informed nodular regenerative hyperplasia. Thus, the different factors that could explain this pathology are analyzed. B, a monoclonal antibody against vascular endothelial growth factor, reduces the anti-apoptotic, anti-inflammatory and survival effects produced by this factor, affecting the vascular protection of the endothelial cell. On the other hand, OX activates metalloproteinasesand depletes sinusoidal glutathione producing sinusoidal lesions. Thus, (OX) would be associated with sinusoidal obstruction and NRH sporadically. It is important to discuss the possible etiologic factors that can cause NRH reviewing the hepatotoxic effects caused by both drugs.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.141 n.10 20132013-10-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013001000017es10.4067/S0034-98872013001000017
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Antibodies monoclonal humanized Bevacizumab Focal nodular hyperplasia Hypertension portal Organometallic compounds Oxaliplatin
spellingShingle	Antibodies monoclonal humanized Bevacizumab Focal nodular hyperplasia Hypertension portal Organometallic compounds Oxaliplatin Fluxá C,Daniela Salas M,Sebastián Regonesi M,Carlos Contreras M,Luis Wash F,Alex Silva P,Guillermo Trombosis venosa portal e hiperplasia nodular regenerativa hepática; posible efecto adverso asociado a bevacizumab y oxaliplatino
description	Nodular regenerative hyperplasia (NRH) consists in diffuse transformation of the hepatic parenchyma into small regenerative nodules without fibrosis, secondary to vascular occlusion and flow alterations. This gives a nodular appearance to theliver, as there is atrophy and compensatory hypertrophy of hepatocytes. We reporta 69-year-old male who suffered of colon cancer and was treated with Oxaliplatin (OX) and Bevacizumab (B). During treatment with B the patient presented a partial thrombosis of the portal vein, that one year later became permeable. Esophageal varices were found in an upper digestive endoscopy. Hepatic tests were normal. Aliver biopsy was performed and informed nodular regenerative hyperplasia. Thus, the different factors that could explain this pathology are analyzed. B, a monoclonal antibody against vascular endothelial growth factor, reduces the anti-apoptotic, anti-inflammatory and survival effects produced by this factor, affecting the vascular protection of the endothelial cell. On the other hand, OX activates metalloproteinasesand depletes sinusoidal glutathione producing sinusoidal lesions. Thus, (OX) would be associated with sinusoidal obstruction and NRH sporadically. It is important to discuss the possible etiologic factors that can cause NRH reviewing the hepatotoxic effects caused by both drugs.
author	Fluxá C,Daniela Salas M,Sebastián Regonesi M,Carlos Contreras M,Luis Wash F,Alex Silva P,Guillermo
author_facet	Fluxá C,Daniela Salas M,Sebastián Regonesi M,Carlos Contreras M,Luis Wash F,Alex Silva P,Guillermo
author_sort	Fluxá C,Daniela
title	Trombosis venosa portal e hiperplasia nodular regenerativa hepática; posible efecto adverso asociado a bevacizumab y oxaliplatino
title_short	Trombosis venosa portal e hiperplasia nodular regenerativa hepática; posible efecto adverso asociado a bevacizumab y oxaliplatino
title_full	Trombosis venosa portal e hiperplasia nodular regenerativa hepática; posible efecto adverso asociado a bevacizumab y oxaliplatino
title_fullStr	Trombosis venosa portal e hiperplasia nodular regenerativa hepática; posible efecto adverso asociado a bevacizumab y oxaliplatino
title_full_unstemmed	Trombosis venosa portal e hiperplasia nodular regenerativa hepática; posible efecto adverso asociado a bevacizumab y oxaliplatino
title_sort	trombosis venosa portal e hiperplasia nodular regenerativa hepática; posible efecto adverso asociado a bevacizumab y oxaliplatino
publisher	Sociedad Médica de Santiago
publishDate	2013
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013001000017
work_keys_str_mv	AT fluxacdaniela trombosisvenosaportalehiperplasianodularregenerativahepaticaposibleefectoadversoasociadoabevacizumabyoxaliplatino AT salasmsebastian trombosisvenosaportalehiperplasianodularregenerativahepaticaposibleefectoadversoasociadoabevacizumabyoxaliplatino AT regonesimcarlos trombosisvenosaportalehiperplasianodularregenerativahepaticaposibleefectoadversoasociadoabevacizumabyoxaliplatino AT contrerasmluis trombosisvenosaportalehiperplasianodularregenerativahepaticaposibleefectoadversoasociadoabevacizumabyoxaliplatino AT washfalex trombosisvenosaportalehiperplasianodularregenerativahepaticaposibleefectoadversoasociadoabevacizumabyoxaliplatino AT silvapguillermo trombosisvenosaportalehiperplasianodularregenerativahepaticaposibleefectoadversoasociadoabevacizumabyoxaliplatino
_version_	1718436719160721408

Trombosis venosa portal e hiperplasia nodular regenerativa hepática; posible efecto adverso asociado a bevacizumab y oxaliplatino

Ejemplares similares